Item 5.07 Submission of Matters to a Vote
of Security Holders
At the Extraordinary General Meeting, holders
of 35,653,664 of the Company’s ordinary shares, which represents approximately 68.9% of the ordinary shares outstanding and
entitled to vote as of the record date of January 9, 2023, were represented in person or by proxy.
At the Extraordinary General Meeting, the
shareholders approved (1) a special resolution to amend Articles 51.7 and 51.8 of the Company’s second amended and restated
memorandum and articles of association (the “Second MAA”), in accordance with the form set forth in Annex B to the accompanying
proxy statement, to extend the date (the “Termination Date”) by which the Company must (i) consummate a merger, capital stock
exchange, asset acquisition, share purchase, reorganization or similar business combination involving the Company and one or more businesses,
which we refer to as a “business combination,” or (ii) cease its operations except for the purpose of winding up if it fails
to complete such business combination and redeem or repurchase 100% of the Company’s public shares included as part of the units
sold in the Company’s initial public offering that was consummated on February 9, 2021, which we refer to as the “IPO,”
(the “Extension”) from February 9, 2023 to March 9, 2023 (the “First Extended Date”),
and if the Company does not consummate a business combination by the First Extended Date, the period of time to consummate a business
combination may be extended, without the approval of the Company’s shareholders, by resolutions of the Board (as defined below)
of the Company at least three days prior to First Extended Date, and to April 9, 2023 (the “Second Extended Date”); and may
be further extended, by resolutions of the Board passed at least three days prior to the Second Extended Date, to May 9, 2023 (the “Third
Extended Date”, and each of the First Extended Date, the Second Extended Date and the Third Extended Date, an “Extended Date”),
for two additional one-month periods, for an aggregate of two months (each, an “Additional Extension Period”) (the “Extension
Amendment Proposal”) and (2) the proposal to approve the Trust Amendment (the “Trust Amendment Proposal,” and together
with the Extension Amendment Proposal, the “Extension Proposals” ). A copy of the amendment to our Second MAA is attached
to this Current Report on Form 8-K as Exhibit 3.1 and incorporated herein by reference.
1. | The Extension Amendment Proposal. The Extension Amendment Proposal was approved. The final voting
tabulation for this proposal was as follows: |
FOR | |
AGAINST | |
ABSTAIN |
35,540,225 | |
113,439 | |
0 |
2. | The Trust Amendment Proposal. The Trust Amendment Proposal was approved. The final voting tabulation
for this proposal was as follows: |
FOR | |
AGAINST | |
ABSTAIN |
35,539,362 | |
114,302 | |
0 |
In connection with the vote to approve the
Extension Proposals, the holders of 31,281,090 Class A ordinary shares elected to redeem their shares for cash at a redemption price
of approximately $10.18 per share, for an aggregate redemption amount of approximately $318.6 million, leaving approximately $103.1
million in the trust account.
The information included in Item 1.01 is incorporated
by reference in this item to the extent required herein.
The proposal to adjourn
the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event
that there were insufficient votes to approve the Extension Proposals or if the Company determines that additional time is necessary
to effectuate the Extension, was not presented at the Extraordinary General Meeting, as the Extension Amendment Proposal and the Trust
Amendment Proposal received a sufficient number of votes required for approval.
Important Additional Information Will Be Filed
with the SEC
This current report relates to the proposed business
combination between HH&L and DiaCarta (the “Business Combination”). HH&L has filed a preliminary, and will file a
definitive, proxy statement, which will include a prospectus, which will be a part of a registration statement, and other relevant documents
with the SEC. This current report does not contain all the information that should be considered concerning the proposed Business Combination
and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. HH&L’s
and DiaCarta’s shareholders and other interested persons are urged to read the proxy statement/prospectus and any other relevant
documents filed with the SEC when they become available, and any amendments thereto, because, among other things, they will contain updates
to the financial, industry and other information herein as well as important information about HH&L, DiaCarta and the contemplated
Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed Business
Combination will be mailed to shareholders of HH&L as of a record date to be established for voting on the proposed Business Combination.
Shareholders will be able to obtain a free copy of the proxy statement/prospectus (when filed), as well as other filings containing information
about HH&L, DiaCarta and the proposed Business Combination, without charge, at the SEC’s website located at www.sec.gov or
by directing a request to: HH&L Acquisition Co., Suite 2001-2002, 20/F, York House, The Landmark, 15 Queen’s Road Central,
Central, Hong Kong. Investment in any securities described herein has not been approved or disapproved by the SEC or any other regulatory
authority nor has any authority passed upon or endorsed the merits of the Business Combination or the accuracy or adequacy of the information
contained herein. Any representation to the contrary is a criminal offense.
Forward-Looking Statements
This current report contains certain statements,
estimates, targets, forecasts, and projections with respect to HH&L or DiaCarta. All statements other than statements of historical
fact are forward-looking statements. Forward-looking statements include, without limitation, statements regarding the estimated future
financial performance and financial position of DiaCarta. Future results are not possible to predict. Opinions and estimates offered
in this current report constitute DiaCarta’s judgment and are subject to change without notice, as are statements about market
trends, which are based on current market conditions. You can identify these forward looking statements through the use of words such
as “may,” “will,” “can,” “anticipate,” “assume,” “should,” “indicate,”
“would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,”
“continue,” “plan,” “point to,” “project,” “predict,” “could,”
“intend,” “target,” “potential” and other similar words and expressions of the future, but the absence
of these words does not necessarily mean that a statement is not forward-looking. Such forward-looking statements are based on estimates,
assumptions and factors that are inherently uncertain, that are beyond DiaCarta’s control or ability to predict and that could
cause actual results to differ materially from expected results. As a result, they are subject to significant risks and uncertainties
and actual events or results may differ materially from these forward-looking statements. No reliance should be placed on, any forward-looking
statements, including any projections, targets, estimates or forecasts contained in this current report. Any forward-looking statement
speaks only as of the date on which it was made, based on information available as of the date of this current report, and such information
may be inaccurate or incomplete. Products described by DiaCarta in its pipeline are under investigation and have not been proven to be
safe or effective, and there is no guarantee any such product will be approved in the sought-after indication or will meet the developmental
milestones set forth herein, including within the timeline set forth herein. Neither DiaCarta, nor HH&L undertakes any obligation
to release any revisions to such forward-looking statements, whether as a result of new information, future events or otherwise, except
as required by law. Information regarding performance by, or businesses associated with, our management team or businesses associated
with them is presented for informational purposes only. Past performance by DiaCarta’s management team and its affiliates is not
a guarantee of future performance. Therefore, you should not rely on the historical record of the performance of DiaCarta’s management
team or businesses associated with them as indicative of DiaCarta’s future performance of an investment or the returns DiaCarta
will, or is likely to, generate going forward.
Participants in the Solicitation
HH&L and its directors and executive officers
may be deemed to be participants in the solicitation of proxies from HH&L’s shareholders in connection with the proposed Business
Combination. A list of the names of HH&L’s directors and executive officers and information regarding their interests in HH&L
is contained in HH&L’s Annual Report on Form 10-K, which was filed with the SEC on March 30, 2022, and is available free of
charge at the SEC’s website at www.sec.gov, or by directing a request to HH&L Acquisition Co., Suite 2001-2002, 20/F, York
House, The Landmark, 15 Queen’s Road Central, Central, Hong Kong. Additional information regarding the interests of any such participants
will be contained in the proxy statement/prospectus for the proposed Business Combination when available.
DiaCarta and its directors and executive officers
may also be deemed to be participants in the solicitation of proxies from the shareholders of HH&L in connection with the proposed
Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed
Business Combination will be included in the proxy statement/prospectus for the proposed Business Combination when available.
The definitive proxy statement/prospectus will
be mailed to shareholders as of a record date to be established for voting on the proposed Business Combination when it becomes available.
Shareholders, potential investors and other interested persons should read the proxy statement/prospectus carefully when in becomes available
before making any voting or investment decisions.
No Offer or Solicitation
This current report is for informational purposes
only and does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of
the Business Combination, (ii) an offer or invitation for the sale or purchase of the securities, assets or business described herein
or a commitment of HH&L, DiaCarta or any of their respective subsidiaries, stockholders, affiliates, representatives, partners, directors,
officers, employees, advisers or agents, with respect to any of the foregoing, nor shall there be any sale of securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction, and this press release shall not form the basis of any contract, commitment or investment decision and does not constitute
either advice or recommendation regarding any securities.